# GSK — GSK · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** GSK  
**Sources:** 17  
**Published:** 2026-10-04  
**Canonical:** https://app.k3vl4r.com/research/deep-research-gsk-gsk-catalysts-narrative-risks-6081

---

# GSK plc (LSE: GSK / NYSE: GSK) — Catalysts, Narrative, Risks, and Calendar

*Not investment advice. The figures below are reported from the cited sources as of the reporting date and should be verified against primary sources before use.*

**Context.** GSK is a FTSE 100 pharmaceutical/biotech group with a primary listing on the London Stock Exchange and ADRs on the NYSE, reporting in GBP on LSE and USD on NYSE. Reported market capitalization sits in the ~$94B range [[12]](https://www.marketbeat.com/stocks/NYSE/GSK/news/), [[14]](https://stockanalysis.com/stocks/gsk/), versus ~$122.6B cited by Wikipedia for February 2026 [[17]](https://en.wikipedia.org/wiki/GSK_plc). Below are the material developments over roughly the past one to three months (July–September 2026).

## Recent catalysts (July–September 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-gsk-gsk-catalysts-narrative-risks-6081 (free to sign up)._
